Ken Griffin Sellas Life Sciences Group, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 147,400 shares of SLS stock, worth $184,250. This represents 0.0% of its overall portfolio holdings.
Number of Shares
147,400
Previous 266,000
44.59%
Holding current value
$184,250
Previous $281,000
47.33%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding SLS
# of Institutions
35Shares Held
8.03MCall Options Held
2.52MPut Options Held
24.7K-
Anson Funds Management LP Dallas, TX4.83MShares$6.04 Million0.8% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.51MShares$1.89 Million0.0% of portfolio
-
Empery Asset Management, LP New York, NY308KShares$385,5823.71% of portfolio
-
Black Rock Inc. New York, NY278KShares$347,7720.0% of portfolio
-
Geode Capital Management, LLC Boston, MA273KShares$341,3280.0% of portfolio
About SELLAS Life Sciences Group, Inc.
- Ticker SLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,551,900
- Market Cap $25.7M
- Description
- SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...